Volitionrx Limited · AMEX:VNRX
Volitionrx — Investor Presentation (January 2025)
37 slides from Volitionrx's investor presentation, January 2025
Slide 1: Corporate Deck January 2025
NYSE:VNRX Corporate Deck January 2025 Property of Volition© 2025 Slide 1
Slide 2: Forward Looking Statements and Disclaimer
Forward Looking Statements and Disclaimer Statements in this document may be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncer
Slide 3: Our mission is to save lives and improve outcomes
Our mission is to save lives and improve outcomes for millions of people and animals worldwide. Property of Volition© 2025 Slide 3
Slide 4: At-a-Glance
At-a-Glance VolitionRx Our Focus Commercial Multi-National • (NYSE: VNRX) • Advancing low-cost, Validation • 85 employees • Diagnostics early detection and • Commercial • 27,000 square foot lab (epigenetics) treatment monitoring launches worldwide and production spaces ✓Commercial tests in animal he
Slide 5: Investment Highlights
Investment Highlights Commercial Progress Large Unmet Needs • Nu.Q® Vet Cancer test now available in 20 countries • Lung Cancer Screening – screening, prognostics and • Sold >110,000 tests and test components Q1-Q3 2024 MRD represent a $1.8B opportunity • Received $23 million in upfront and mileston
Slide 6: Nu.Q Vet
Nu.Q® Vet • Licensed to two of the largest veterinary service companies world-wide • Available via reference labs and at point-of-care in-clinic exclusively with Antech • Nu Q® Vet Cancer Test developed with the goal of providing an accessible and affordable screening test to aid in early cancer det
Slide 7: Licensing Portfolio: Platform stable, reproducible
Licensing Portfolio: Platform stable, reproducible Application Proof of Concept Viability Validation Licensed Animal Canine Cancer Screening Launched Canine Cancer Monitoring Feline Cancer Automated test In negotiation Human Sepsis Data room available Cancer Lung Cancer Screening MRD & Disease Data
Slide 8: Executive Team
Executive Team Cameron Reynolds MBA, Terig Hughes Gaetan Michel PhD Louise Batchelor Andrew Retter Jake Micallef, PhD President & Group CEO Group CFO COO Group CMO and Chief Medical Officer CSO Comm. Officer Gael Forterre, MBA Jasmine Kway PhD Tom Butera DVM Nick Plummer, Rodney Rootsaert CCO CEO, V
Slide 9: What sets us apart?
What sets us apart? • Our tests are simple, low-cost accessible routine blood tests • Platform agnostic, can be adapted to any diagnostic workflow • Manual, Reference Lab, Specialist Lab and Point of Care Six Hours 45 minutes <10 minutes <15 minutes • Our expanding Intellectual Property portfolio •
Slide 10: Go-to-Market Strategy
Go-to-Market Strategy R&D • R&D conducted by Volition and its research partners • Monetize IP through licensing agreements with upfront payments, milestone payments, royalties and sales of key components Non-exclusive licensing and partnering criteria: ✓ Broad geographic reach ✓ Large installed base
Slide 11: The Science Behind Our Technologies
The Science Behind Our Technologies Chromatin Chromosome Nucleosome Cancer and cell death cause chromatin CTCF fragmentation Sequence only present on CTCF in cancer Property of Volition© 2025 Slide 11
Slide 12: Nu.Q Vet Cancer Test
Nu.Q® Vet Cancer Test Property of Volition Veterinary Diagnostics Development© 2025 Slide 12
Slide 13: Nu.Q Vet Cancer Test availability and sales
Now Sold > 110,000 available in Nu.Q® Vet Cancer Revenue Tests & Test 20 countries Components YTD +307% Q3 and growing! 2024 2024 vs Q3 PY Property of Volition Veterinary Diagnostics Development© 2025 Slide 13
Slide 14: Licensing & Supply Agreements to-date
Licensing & Supply Agreements to-date • Launched with IDEXX in the U.S Jan ‘23 • Launched in U.S. / Aus • Launched in UK & Ireland Nov ‘23 /HK/Singapore/ some EU countries April ‘24 • Launched July ‘24 • Launched in Portugal • Launched in Nov ‘22 Singapore Nov ‘23 • Launched in Taiwan Nov ‘23 • Laun
Slide 15: Nu.Q exclusively available in-house with Antech
Nu.Q® exclusively available in-house with Antech Exclusive Heska Element i+ in-house analyzer licensing partnershjp with Antech $10M upfront and $13M milestone payments received to-date. $5M milestone payment linked to use in felines remaining Launched April 2024 Ongoing revenue from the purchase of
Slide 16: Nu.Q Vet Cancer Test on the Element i+ Analyzer
Nu.Q® Vet Cancer Test on the Element i+ Analyzer Immediate Results (<10 mins) Accurate (detects 76% of systemic cancers at 97% specificity) Cost effective ($35 to the vet) Allowing veterinarian to make informed clinical decisions quickly in-house – whilst the patient is still in clinic Property of V
Slide 17: Development Pipeline
Development Pipeline Screening & Platform Monitoring development: Cancer in automated Cats Treatment & Disease NETosis in Monitoring animals Application Property of Volition Veterinary Diagnostics Development© 2024 2025 Slide 17
Slide 18: Licensing Portfolio
Licensing Portfolio Property of Volition© 2025 Slide 18
Slide 19: Sepsis & Thrombosis
Sepsis & Thrombosis Property of Volition© 2025 Slide 19
Slide 20: Property of Volition © 2025 Slide 20
Property of Volition© 2025 Slide 20
Slide 21: Neutrophil Extracellular Traps (NETs)
Neutrophil Extracellular Traps (NETs) NETs: • are produced by ejecting chromosomal material out of the cell • catch and kill bacteria and viruses • can sterilize blood in minutes • first reported in 20041 • now the subject of > 5000 publications 1. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhle
Slide 22: 1 in 5 deaths worldwide are associated with sepsis
1 in 5 deaths worldwide are associated with sepsis It’s the number 1... Almost 50 million cases resulting in Cause of death in Over 40% of 11 million deaths hospitals survivors suffer from long-term physical Over 40% of cases Cause for hospital or psychological are children under readmissions effec
Slide 23: Unmet Needs
Unmet Needs • Current diagnosis is empirical, multi-factorial and subjective. • CURRENT methods of assessment (SOFA and APACHE II) are both complex & slow. • Accepted need for improved diagnostics1. 1. Rudd et al. 2020 The Lancet doi: 10.1016/S0140-6736(19)32989-7. Property of Volition© 2025 Slide 2
Slide 24: Studies at Centers of Excellence: >3000 patients
Studies at Centers of Excellence: >3000 patients Study Country Description Cohort Size SISPCT Germany Retrospective analysis of 971 intensive care patients prospectively collected cohort Multiple timepoints Amsterdam Netherlands Retrospective analysis of 1,713 intensive care patients UMC prospective
Slide 25: Executive Summary: consolidated conclusions
Executive Summary: consolidated conclusions Results from three independent studies totalling over 3,000 patients These findings are consistent across cohorts1-3 An elevated H3.1 level reflects a dysregulated immune response and is associated with: • a risk of increased mortality • an increased risk
Slide 26: NETs: Casting a new light on sepsis management
NETs: Casting a new light on sepsis management Satellite Symposium at ESICM LIVES 2024 Prof. Djillali Annane Professor of Medicine, University Paris Saclay-UVSQ, France “As a Critical Care Consultant, I see the devastating effects of this disease each day. I believe Nu.Q® NETs, as a diagnostic tool,
Slide 27: Our focus…
Our focus… To develop a low-cost, routine test to stratify risk of sepsis particularly those at risk of progressing to multiple organ failure; in addition to monitoring the disease progression and response to treatment. • Data from several large-scale studies presented at ESICM LIVES 20241 • Manuscr
Slide 28: Property of Volition © 2025 Slide 28
Property of Volition© 2025 Slide 28
Slide 29: Low-cost, routine and accessible tests
• Low-cost, routine and accessible tests to help detect and monitor disease progression and aid treatment selection Property of Volition© 2025 Slide 29
Slide 30: Potential applications of a blood test in lung cancer
Potential applications of a blood test in lung cancer: Nu.Q® addresses all five Property of Volition© 2025 Slide 30
Slide 31: Study Overviews
Study Overviews • Range of studies from prospective and retrospective, blinded, longitudinal studies of lung cancer. • Cohort sizes – ranging from 70 to 800 patients. • Covering detection of lung cancer at diagnosis and during treatment • KEY Outcome measures to demonstrate CLINICAL UTILITY (correla
Slide 32: Our Focus
Our Focus To develop low-cost, routine tests to help: • detect disease early • provide tailored treatment • assess response to treatment • identify MRD • support continued treatment decisions Many data in the Confidential Data Room • NTU lung paper available on MedRXIV • Lyon data presented at AACR
Slide 33: Proof of Concept
Proof of Concept: Potential Breakthrough Cancer Detection Method1. • Novel wet chemistry pathway for ctDNA analysis • Discovered a completely new class of biomarkers that are invisible to current methods and demonstrated that they can be isolated as pure ctDNA • Identified hundreds of potential shor
Slide 34: Summary
Summary Property of Volition© 2025 Slide 34
Slide 35: Go-to-Market Strategy
Go-to-Market Strategy R&D • R&D conducted by Volition and its research partners • Monetize IP through commercial contracts with upfront payments, milestone payments, royalties and sales of key components Non-exclusive licensing and partnering criteria: ✓ Broad geographic reach ✓ Large installed base
Slide 36: Investment Summary
Investment Summary • Listed, commercial stage diagnostics company — developing low-cost, early detection and treatment monitoring diagnostics in human and animal health • Disease areas – global killers: Cancer, Sepsis; significant market opportunities • Human and Veterinary use cases: • Screening •
Slide 37: Questions?
Questions? Thank you for your interest in Volition. For more details, please visit www.volition.com Property of Volition© 2025 Slide 37